{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"35","value":"238"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Cmax was the concentration of study drug in the blood after the dose is administered. It was measured post-dose and was summarized using descriptive statistics.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received the following treatments in a 28-day cycle, continuing until disease progression or a criterion for discontinuation was met.\n\n* Ramucirumab administered intravenously at a dose of 12 mg/kg as a one-hour infusion on days 1 and 15.\n* Cyclophosphamide administered orally at 25 mg/m² daily from days 1 to 28.\n* Vinorelbine administered intravenously at 25 mg/m² on days 1, 8, and 15.","id":"OG000","title":"Ramucirumab + Cyclophosphamide + Vinorelbine"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All randomized participants who received at least one dose of Ramucirumab and had evaluable PK data for this outcome.","reportingStatus":"POSTED","timeFrame":"End of ramucirumab infusion on Day 1 of Cycle 1","title":"Pharmacokinetics (PK): Maximum Serum Concentration of Ramucirumab (Cmax)","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}